Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Bay-41-4109: a novel anti-HBV candidate

Aug. 1, 2002

FDA approves Zelnorm for IBS in women with constipation

July 26, 2002

Chimeric form of anti-CD40 MAb prepared by Tanox and proven safe and effective in animals

July 25, 2002

CP-461 enters phase II pilot trial in Crohn's disease

July 24, 2002

Yamanouchi licenses North American development and marketing rights to Z-338

July 18, 2002

FDA grants priority review for Pegasys combination treatment

July 17, 2002

Amrad discontinues development of AM-365

July 15, 2002

Chiron licenses hepatitis C targets to Abbott

July 15, 2002

Novel anti-H. pylori agents claimed in Shionogi patent

July 12, 2002

Phase I trial initiated with visilizumab in patients with ulcerative colitis

July 12, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...